William Lee, MD
Cornea and External Diseases Specialist · Atlanta, GANPI 1366406787
Payments from drug & device makers
Across 1,030 payments — averaging $529.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$148K
- Sun Pharmaceutical Industries Inc.$109K
- Oyster Point Pharma, Inc.$75K
- Glaukos Corporation$43K
- Dompe US, Inc.$42K
- Eyevance Pharmaceuticals LLC$38K
- plus $91K from 30 others
What the payments were for
- Consulting fees$67,56313%
- Speaking & faculty fees$352,62070%
- Travel & lodging$49,25010%
- Food & beverage$31,8946%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$144,907
- XIIDRA$139,197
- CEQUA$106,141
- Oxervate$40,857
- TYRVAYA$28,914
- Zerviate$13,781
- Flarex$12,612
- Tobradex ST$10,771
- KXL System$8,614
- EYSUVIS$7,070
- DEXYCU$6,954
- CE-marked KXLA system$6,854
- INVELTYS$5,539
- Prokera$5,070
- AmnioGraft$5,070
- AmnioGuard$5,070
- Travoprost Intraocular Implant - iDose$2,619
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$2,500
- XDEMVY$2,236
- DEXTENZA$1,950
How this compares
Too few cornea and external diseases specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 31 | $1,220,858 |
| RestasisCyclosporine | 112 | $117,082 |
| XiidraLifitegrast | 69 | $78,011 |
| Prednisolone Acetate | 943 | $38,790 |
| CequaCyclosporine | 42 | $26,532 |
| MieboPerfluorohexyloctane/Pf | 28 | $22,632 |
| Cyclosporine | 32 | $19,628 |
| LumiganBimatoprost | 31 | $18,114 |
| ProlensaBromfenac Sodium | 51 | $17,850 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $12,317 |
| TyrvayaVarenicline Tartrate | 16 | $11,776 |
| Difluprednate | 91 | $8,391 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 59 | $8,248 |
| Loteprednol Etabonate | 56 | $7,683 |
| Alphagan PBrimonidine Tartrate | 18 | $7,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $41,638 | $1,220,85831 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,170 | $155,083207 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan | $148,049 | $105,718108 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $358 | $31,055129 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $108,693 | $26,53242 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $75,390 | $11,77616 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $12,917 | $5,02417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Atlanta
- Joseph ChristenburyAtlanta$262K
- Soroosh BehshadAtlanta$7K
- Evan LoftAtlanta$2K
- Amit BajajAtlanta$1K
- Colton McCoyAtlanta$553
- Amy EstesAugusta$2K
- Abigail KalishMarietta$1K
- Barbara SmithMarietta$633
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.